Pancreatic cancer-derived exosomes promote tumor metastasis and liver pre-metastatic niche formation

Zeqian Yu1,2, Susu Zhao3, Long Ren1, Lishan Wang1, Zhangjun Chen1,2, Robert M. Hoffman4,5 and Jiahua Zhou1,2

1Department of Hepatic-Biliary-Pancreatic Center, Zhongda Hospital, Southeast University, Nanjing, China
2Department of Hepatobiliary Surgery Research Institute, Southeast University, Nanjing, China
3Department of Pathology, Traditional Chinese Medicine Hospital of Jiangsu Province, Nanjing, China
4Department of Surgery, University of California at San Diego, San Diego, California, USA
5AntiCancer, Inc., San Diego, California, USA

Correspondence to: Jiahua Zhou, email: zhoujh@seu.edu.cn

Keywords: pancreatic cancer, exosomes, pre-metastatic niche, proteomics, iTRAQ

Received: March 31, 2017 Accepeted: June 01, 2017 Published: June 28, 2017

ABSTRACT

Exosomes play important roles in cell-cell communication, and are likely mediators of the metastatic cascade in cancer. This study examined the role of exosomes in pancreatic cancer cell adhesion, migration, and invasion. We isolated and purified exosomes from two isogenic pancreatic cancer cell lines with different metastatic potentials. Uptake of exosomes from highly metastatic Panc02-H7 cells decreased adhesion and increased migration and invasion capacity in weakly metastatic Panc02 cells in vitro. Exosomes from highly metastatic pancreatic cancer cells induced liver pre-metastatic niche formation in naïve mice and promoted primary tumor growth and liver metastasis in vivo. We identified 4,517 proteins in exosomes from Panc02 and Panc02-H7 cells via iTRAQ quantitative proteomic analyses, 79 of which were differentially expressed between the two cell lines. Bioinformatics analyses showed that most of the differentially expressed proteins were involved in pancreatic cancer growth, invasion, and metastasis, and that metabolism-related signaling pathways were involved in exosome-mediated intracellular communication. Further studies will be needed to determine whether these proteins are potential pancreatic cancer diagnostic/prognostic markers or novel therapeutic targets.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies, and is one of the five most common causes of cancer mortality worldwide. An estimated 53,070 new pancreatic cancer cases will be diagnosed and 41,780 patients will die from pancreatic cancer in the United States in 2017 [1]. Rising incidence and mortality rates were also observed in 2015 in China [2]. Despite some progress in surgical techniques, chemotherapy, and radiotherapy, pancreatic cancer patient prognosis is extremely poor, with an overall 5-year survival rate <6%. Median survival is 8–12 months for patients with locally advanced disease, and only 3–6 months for those with metastatic disease [3]. Accurate diagnostic biomarkers to detect pancreatic cancer at an earlier stage, and novel therapeutic strategies that target metastatic disease are urgently needed to improve patient outcomes.

The tumor microenvironment comprises cancer and stromal cells, along with extracellular matrix (ECM) components and secreted soluble factors, such as chemokines, cytokines, and growth factors. These soluble factors facilitate cell-cell communication, tumor...
progression and metastasis, and pre-metastatic niche generation in distant organs. Recent studies identified tumor-derived exosomes as key modulators of the tumor microenvironment that mediate cell-cell communication and eventually induce metastatic niche formation [4].

Exosomes are 40–100 nm diameter vesicles derived from late endosome/multivesicular body (MVB) luminal membranes, and are constitutively released via fusion of MVBs with the cell membrane under both physiological and pathological conditions. Exosomes are enriched in parent cell-derived bioactive molecules, including proteins, RNAs, and lipids, which can be horizontally transferred to recipient cells and regulate their function [5]. Specific proteins have been identified in PDAC exosomes [6–10], but a comparative proteomics analysis of exosomes secreted by PDAC cell lines of different metastatic potential has not been performed. The present study used iTRAQ-quantitative proteomic analysis to identify the protein compositions of exosomes derived from two isogenic PDAC cell lines, Panc02 and Panc02-H7, which differ in their degree of metastatic potential [11]. We identified potential key proteins that facilitate crosstalk between the primary tumor and the microenvironment, and which may be useful biomarkers for PDAC diagnosis and prognosis.

RESULTS

Panc02 EXO and Panc02-H7 EXO characterization

Purified exosomes were isolated using ultracentrifugation combined with sucrose density gradient centrifugation (Figure 1A). Western blotting confirmed the presence of several classical common exosome markers, including TSG101, CD9, and MHC-I (Figure 1B). Cytochrome c, a mitochondrial marker, was detected in two whole cell lysates, but was absent from exosomes, indicating that the exosomes were not contaminated with other vesicles (Figure 1B). Sizes and morphological characteristics of exosomes derived from two pancreatic cancer cell lines were assessed via transmission electron microscopy (TEM). Exosomes from both cell lines were cup-shaped and ranged from 50–150 nm in diameter (Figure 1C). Exosomes from the highly metastatic pancreatic cancer cell line (Panc02-H7 EXO) expressed more total protein than exosomes from the poorly metastatic cell line (Panc02 EXO) (Figure 1D).

Panc02-H7-derived exosomes decreased adhesion and increased migration and invasion in recipient cells

We incubated PKH67-labeled Panc02-H7 EXOs with Panc02 cells. After five h, numerous green fluorescent exosomes were observed inside Panc02 cells via fluorescence microscopy. Exosomes were mainly located at the perinuclear region, suggesting Panc02 cell uptake of Panc02-H7 EXOs (Figure 2A). We speculated that exosome cargo release might affect recipient cell metastatic capabilities. Therefore, we analyzed recipient cell adhesion, migratory, and invasive potential following exosome internalization. Amiloride reportedly depresses cell exosome secretion [12]. In the MTT cell adhesion assay, Panc02 cells exposed to PBS (control group), 100 μg/ml Panc02-H7 EXOs (EXO group), or 7 mmol/Lamiloride (Exo-D group) for 24 h were inoculated into 96-well plates in serum-free medium. Cell attachment was greater in the Exo-D group than in the EXO and control groups (Figure 2B), indicating that Panc02-H7 EXOs may decrease Panc02 cell adhesion. In a wound-healing assay, migration was increased in the EXO group compared to the control and Exo-D groups (Figure 2C). Similarly, transwell chamber invasion assays results showed increased invasion by EXO group cells compared to control and Exo-D cells (Figure 2D). Western blotting results showed that CXCR4 and MMP-9 levels were higher in the EXO group than in the control group, but were reduced in the Exo-D group (Figure 2E). These results suggest that exosomes from high metastatic-potential cells can induce metastatic behavior in Panc02 cells.

Exosome tissue distribution and liver pre-metastatic niche formation

Exosome biodistribution in liver, lung, spleen, kidney, brain, and bone marrow was assessed 24h post-injection (hpi) of exosomes using confocal microscopic analysis. Pancreatic cancer-derived exosomes accumulated in the lung, liver, and spleen, with less accumulation in the brain and bone marrow compared to a liposome control (Figure 3A). Panc02-H7 cell-derived exosomes accumulated at higher levels in the lung, liver, and bone marrow than exosomes from Panc02 cells (Figure 3A).

Immunofluorescence (IF) quantitative analysis showed that Panc02-H7 EXOs increased the frequency of CD11b+ (also confirmed by Western blotting) and CD45+ hematopoietic progenitor cells at pre-metastatic sites after 12 d compared with Panc02 EXO and control groups (Figure 3B). Pancreatic cancer-derived exosomes also induced Stat3 activation and myeloid infiltration (over 12 d of treatment). Stat3 activity was detectable in myeloid cells and in the liver (Figure 3B). We observed increased alpha smooth muscle actin (α-SMA)+ hepatic stellate cells (hStCs) and fibronectin (FN) upregulation in mice treated with Panc02-H7 EXOs compared with Panc02 EXOs and controls. We found a predominant α-SMA+ cell population in FN-enriched liver areas in mice treated with Panc02-H7 EXOs, suggesting that activated hStCs produced most of the FN (Figure 3C). Western blotting analysis showed upregulated S100A8 and S100A9 in...
Panc02-H7 EXO-treated livers (Figure 3D). Panc02-H7 EXOs increased myeloid-derived suppressor cell (MDSC) (CD11b^+Gr1^+ cell) frequency in peripheral blood more than Panc02 EXOs and the control group (Figure 3E).

**Tumor-derived exosomes promote pancreatic cancer growth, micrometastasis, and metastasis**

We administered Panc02-H7 EXOs and Panc02 EXOs (10 μg) intravenously (tail vein) into C57BL/6 mice three d per week, starting seven d after pancreatic cancer surgical orthotopic implantation (SOI). Primary tumor volume only increased at 30 d post-SOI (Figure 4B). In contrast to controls, only Panc02-H7 EXO-treated mice exhibited lung and liver micrometastasis at d 15 (Figure 4C). These mice also had a greater metastatic burden and cancer cell distribution in the liver, lung, diaphragm, pleura, adrenal gland, small intestine, lymph nodes, and spleen compared to PBS- or Panc02 EXO-treated mice (Figure 4A). These data suggest that qualitative exosome content differences can mediate metastatic potential and organ tropism.

S100A8 and S100A9 were upregulated, and F4/80^+ macrophages, α-SMA^+ hStCs, and neutrophils were increased in Panc02-H7 EXO-treated mouse livers compared with untreated, Panc02 EXO-, or PBS-treated livers (Figure 5A–5B & 5C–5E). There was no difference between the Panc02 EXO and control groups. Immunohistochemical (IHC) analyses and Masson's trichrome staining showed that FN was upregulated in Panc02-H7 EXO-treated mouse livers. Connective tissue deposition was increased in mouse livers treated with either type of exosome compared with control and normal liver, with no difference between the two exosomes.

---

**Figure 1: Characterization of Panc02- and Panc02-H7-derived exosomes.** Exosome isolation and purification schematic (A) Common exosome markers, including TSG101, CD9, and MHC-I, were detected in two exosomes (B) Cytochrome c was detectable in two whole-cell lysates, but not in exosomes. Panc02 EXOs and Panc02-H7 EXOs were negatively stained with 3% phosphotungstic acid and viewed by TEM (scale bar = 200 nm) (C) Total protein per million cells in two exosomes (D) Panc02-H7 EXOs expressed more total protein than Panc02 EXOs. (*P<0.05).
(Figure 5C–5D). These data suggest that pancreatic cancer-derived exosomes may reprogram the liver to form liver metastatic niches.

**Exosomal protein identification via iTRAQ-based proteomic analysis**

Ultimately, 65,077 unique spectra, 22,912 unique peptides, and 4,517 proteins were identified via iTRAQ-based proteomic analysis in the two types of pancreatic cancer exosomes, 71.09% of which were identified with ≥2 peptide matches (Supplementary Table 1). The 4,517 common exosome proteins were classified into three groups, cellular components, molecular function, and biological process, through Blast2go to assess gene ontology (GO) enrichment (Figure 6). Based on different molecular functions, these proteins were grouped as follows: binding, catalytic activity, enzyme regulator activity, transporter activity, structural molecule activity, and transcription factors. The common exosomal proteins are mainly involved in metabolic, structural, and regulating processes. Table 1 shows the top 25 pathways involving these proteins.

**Bioinformatic analysis of proteins differentially expressed between high- and low-metastatic exosomes**

79 proteins were differentially expressed between high- and low-metastatic exosomes (Table 2). We again performed a Blast2go analysis to assess protein gene ontology (GO) enrichment (Figure 7).

**Validation of differentially expressed proteins identified by iTRAQ quantitative proteomics**

We validated six candidate proteins using Western blotting. SBP1, CKAP4, and ALDOC were downregulated, and FAR2, IGF2BP1, and S100A11 were upregulated in Panc02-H7 EXOs compared to Panc02EXOs (Figure 2).

**Figure 2: Panc02-H7-derived exosomes promote metastasis-related characteristics in vitro.** Panc02 cells took up PKH67-labeled Panc02-H7EXOs. Numerous green fluorescently-labeled exosomes were observed inside cells after 5 h (400× magnification). (A) The MTT cell adhesion assay indicated that Panc02-H7 EXOs decrease Panc02 cell adhesion, (B) Wound-healing assays indicated that Panc02-H7 EXOs enhanced Panc02 cell migration (200×magnification). (C) Transwell chamber invasion assays showed that Panc02-H7 EXOs increased Panc02 cell invasion (200×magnification). (D) Western blotting indicated that Panc02-H7 EXOs increased Panc02 cell migration and invasion via CXCR4 and MMP-9 signaling. (E) n=3/group, *P<0.05, **P<0.01, ***P<0.001 compared to control; #P<0.05, ##P<0.01, ###P<0.001 compared to EXO-D.
Figure 3: Pancreatic cancer-derived exosomes mediate liver pre-metastatic niche formation. Confocal microscopy (lung, liver, spleen, brain) of PKH67-labeled Panc02 EXO and Panc02-H7 EXO tissue distribution (green) 24 hpi. (A) PKH-67-labeled liposomes served as controls (scale bar=100 μm). Histogram shows exosome tissue distribution quantification (n=5/group). CD45, p-Stat3, and CD11b IF staining in liver sections from controls (left) and mice treated with Panc02 EXOs (middle) or Panc02-H7 EXOs (right) for 12 d without tumor challenge. (B) Histogram shows infiltrating CD45+ cell quantification. FN and α-SMA IF staining in liver sections from controls (top) and mice treated with Panc02 EXOs (middle) or Panc02-H7 EXOs (bottom) for 12 d without tumor challenge. (C) Histogram shows infiltrating α-SMA+hStCs and FN expression quantification (400× magnification; n=5/group). Western blotting analysis showed upregulated S100A8 and S100A9 in livers treated with Panc02-H7-derived exosomes. Histogram shows expression of the three proteins in three groups determined by densitometric analysis (n=3/group). (D) Pancreatic cancer-derived exosomes induce MDSC accumulation in peripheral blood. (E) Representative flow cytometric plots (left) and quantification (right) of CD11b’GR1+ MDSCs (n=5/group). *P<0.05, **P<0.01, ***P<0.001.
8). GAPDH was used as loading control. Protein band densities analyzed quantitatively using ImageJ verified that expression patterns were consistent with iTRAQ quantitative proteomics results.

**DISCUSSION**

There is currently no standardized exosome isolation technique. In this study, we isolated exosomes by collecting cell-conditioned medium from ordinary culture flasks. We purified exosomes using ultracentrifugation combined with sucrose density gradient centrifugation. However, this method was time-consuming, labor intensive and resulted in low yield. Jeppesen, et al. developed an exosome collection strategy using CLAD1000 bioreactors and a 10-kDa semi-permeable membrane. Their method increases exosome yields 13–16-fold compared to isolation from flasks [13].

Exosomes as cell-free messengers play important roles in cell-cell communication, and are likely mediators of the metastatic cascade [5, 14–16]. This study examined the role of exosomes in cancer adhesion, migration, and invasion. Chemokines and their receptors contribute to cancer metastasis, particularly stromal cell-derived factor-1α and its receptor, CXCR4 [17–18]. MMP-9 is a downstream signaling molecule of CXCR4 and is critical for cancer cell migration and invasion [19]. We found that Panc02-H7 EXO treatment increased Panc02 cell migration and invasion, and upregulated CXCR4 and MMP-9 compared with controls, indicating that CXCR4 and MMP-9 signaling may enhance Panc02 cell metastatic capabilities.

Fluorescent labeling allowed for direct exosome visualization in our study. Consistent with other groups, we found that exosome tissue distribution mimicked the organotropic distribution of the cell line of origin [20].

**Figure 4:** Pancreatic cancer-derived exosomes promote tumor growth and metastasis. Representative macro-anatomy and H&E-stained images of Panc02-H7 EXO-treated mice 30 d post-SOI. (A) A blue star marks primary tumor locations; arrows indicate metastatic sites in the peritoneal cavity. (Aa) Arrows showing lung micrometastasis (Ab), pleura metastasis (Ac), tumor invasion of the diaphragm (Ad), metastasis to spleen ( Ae), tumor invasion of the adrenal gland (Af), metastasis to the kidney (Ag), tumor invasion of the small intestine (Ah), micrometastasis of the liver(lower right shows enlarged image) (Ai), and metastasis to lymph nodes (Aj) (magnification, 100×). Primary tumor volume in mice treated with PBS, Panc02 EXOs, or Panc02-H7 EXOs at 15 and 30 d post-SOI. (B) Number of micrometastases in mice treated with PBS, Panc02 EXOs, or Panc02-H7 EXOs at 15d post-SOI (n=6/group). (C) *P<0.05, **P<0.01, ***P<0.001.
The organotropic nature of exosomes is largely attributed to a specific exosomal surface integrin repertoire that dictates exosome homing to distant organs and uptake by target cells. Our exosome proteomic analysis identified multiple integrin subunits (beta-1, alpha-3, beta-3, beta-4, alpha-5, alpha-V, alpha-6, and alpha-X) (Table 3) that could be associated with pancreatic cancer metastasis to multiple organs. Our model allowed us to study the effects of exosome accumulation in pre-metastatic organs and to determine whether or not such accumulation could prime the liver microenvironment for metastatic tumor cell colonization.

The liver is the main site of metastatic disease from gastrointestinal malignancies, such as pancreatic, colon, and gastric carcinomas. The term “liver pre-metastatic niche” was coined to describe a liver microenvironment permissive to metastatic outgrowth in advance of cancer cell arrival, established through soluble-factor activity and exosome release by the primary tumor. The liver metastatic microenvironment is composed of resident Kupffer cells (KCs), hStCs, bone marrow-derived cells (BMDCs), extracellular matrix components, and secreted soluble factors, such as cytokines and chemokines. Costa-Silva, et al. showed that PDAC-derived exosomes containing macrophage migration inhibitory factor (MIF) are selectively taken up by hepatic KCs, upregulating TGF-β [8]. This increases fibronectin production by hStCs and promotes liver recruitment of bone marrow-derived neutrophils and macrophages, completing pre-metastatic niche formation. Nielsen, et al. showed that metastasis-associated macrophages (MAMs) activate resident hStC transformation into myofibroblasts, resulting in a fibrotic microenvironment that sustains metastatic tumor growth [21]. Macrophages in the liver include embryonically derived tissue-resident macrophages (KCs) and infiltrating macrophages derived from inflammatory monocytes (IMs) that originate from the bone marrow (BM) [22]. These macrophages can also trigger hStC activation and fibrogenesis [23], a process important in the early stages of extra-vascular tumor expansion. Both of these studies emphasized that macrophages play a critical role in the establishment of the liver pre-metastatic niche.

Figure 5: Pancreatic cancer-derived exosomes induce inflammation and fibrotic microenvironment formation in the liver. IHC analysis and histopathological examination of macrophages (F4/80), hStCs (α-SMA), and neutrophils in liver metastatic niches of naïve mice and mice treated with PBS, Panc02 EXOs, or Panc02-H7 EXOs at 30d post-SOI (arrow shows neutrophils in liver). (A) Representative histogram shows quantification of F4/80+ macrophages, α-SMA+ hStCs, and neutrophils. (B) Identification of FN, S100A8, and S100A9 as inflammatory mediators, and collagen deposition in the liver metastatic niche. (C) Representative histogram shows FN and MTS quantification. (D) Representative histogram shows S100A8 and S100A9 quantification. (E) n=6/group. **P<0.01, ***P<0.001. 10 fields assessed per sample. FOV, field of view.
key roles in PDAC liver metastasis. Our IHC analysis results also showed that F4/80+ macrophages were increased in Panc02-H7 EXO-treated livers compared with controls and normal liver. However, F4/80, a cell surface marker used to identify KCs, is also expressed on recruited monocytes, and strategies used to eliminate macrophages in vivo are not KC specific. Thus, our results require further verification.

Under physiological conditions, quiescent hStCs in the space of Disse [24] become activated myofibroblasts that express α-SMA and produce ECM rich in collagens I and IV in response to liver damage, inflammatory stimuli, and tumor cells [25–26]. Chemokines and cytokines released by α-SMA+ hStCs also recruit inflammatory/immune cells and enhance premetastatic niche formation. We observed increased α-SMA hStC frequencies in Panc02-H7 EXO-treated livers, suggesting that activated α-SMA+ hStCs produced most of the FN in both the pre-metastatic and metastatic niches. Masson's trichrome staining also showed higher degrees of fibrosis in livers treated with either Panc02- or Panc02-H7-derived exosomes. We also found that Panc02-H7 EXO treatment increased neutrophil number and upregulated S100A8 and S100A9 in the mouse liver. Neutrophils may be mobilized into liver premetastatic niches by S100A8 and S100A9 or chemokines and cytokines secreted by activated macrophages, endothelial cells, or cancer cells.

Figure 6: Panc02 EXO and Panc02-H7 EXO proteins identified via iTRAQ quantitative proteomic analysis. GO enrichment analysis of 4,517 exosomal proteins via Blast2go. Proteins were classified by cellular component (CC), molecular function (MF), or biological process (BP).
### Table 1: 79 proteins were differentially-expressed between Panc02 EXOs and Panc02-H7 EXOs

| Hits | Accession | Protein name                                                                 | Expression | 114/116 | 119/118 | Mean   |
|------|-----------|------------------------------------------------------------------------------|------------|---------|---------|--------|
| 1    | sp|O88477|IF2B1_MOUSE                                                                   | up         | 1.937   | 2.205   | 2.071  |
| 2    | tr|G3XA48|G3XA48_MOUSE                                                                   | up         | 1.548   | 1.272   | 1.41   |
| 3    | sp|P70460|VASP_MOUSE                                                                    | up         | 1.429   | 1.514   | 1.472  |
| 4    | sp|P47930|FOSL2_MOUSE                                                                   | up         | 1.596   | 1.687   | 1.642  |
| 5    | tr|Q3TT92|Q3TT92_MOUSE                                                                   | up         | 3.193   | 3.973   | 3.583  |
| 6    | sp|Q8K2Q9|SHOT1_MOUSE                                                                   | up         | 1.485   | 1.548   | 1.517  |
| 7    | tr|Q3U125|Q3U125_MOUSE                                                                   | up         | 2.076   | 1.796   | 1.936  |
| 8    | tr|Q3TXR4|Q3TXR4_MOUSE                                                                   | up         | 1.442   | 1.639   | 1.541  |
| 9    | sp|P50543|S10AB_MOUSE                                                                   | up         | 2.692   | 1.942   | 2.317  |
| 10   | tr|Q3TSQ1|Q3TSQ1_MOUSE                                                                   | up         | 1.917   | 1.813   | 1.865  |
| 11   | sp|Q8BV49|IFIX_MOUSE                                                                    | up         | 1.548   | 1.573   | 1.561  |
| 12   | sp|P18406|CYR61_MOUSE                                                                   | up         | 1.359   | 1.529   | 1.444  |
| 13   | sp|Q9CQ69|QCR8_MOUSE                                                                    | up         | 1.353   | 1.983   | 1.668  |
| 14   | sp|P05784|K1C18_MOUSE                                                                   | up         | 1.555   | 1.536   | 1.546  |
| 15   | sp|Q9CR98|F136A_MOUSE                                                                   | up         | 1.539   | 1.254   | 1.397  |
| 16   | tr|E0CXM9|E0CXM9_MOUSE                                                                   | up         | 1.68    | 1.05    | 1.365  |
| 17   | sp|Q9R107|PLP2_MOUSE                                                                    | up         | 2.792   | 1.279   | 2.036  |
| 18   | sp|Q91XV3|BASP1_MOUSE                                                                   | up         | 2.963   | 3.513   | 3.238  |
| 19   | sp|Q9DCV7|K2C7_MOUSE                                                                    | up         | 4.188   | 4.47    | 4.329  |

(Continued)
| Hits | Accession | Protein name | Expression | 114/116 | 119/118 | Mean |
|------|-----------|--------------|------------|---------|---------|------|
| 20   | tr|F6ZFU0|F6ZFU0_MOUSE | Elongation factor 1-delta | up | 1.016 | 1.578 | 1.297 |
| 21   | sp|Q8R5J9|PRAF3_MOUSE | PRA1 family protein 3 | up | 1.32 | 1.599 | 1.46 |
| 22   | tr|D3YUW7|D3YUW7_MOUSE | Cingulin | up | 2.034 | 2.236 | 2.135 |
| 23   | tr|Q3U7D2|Q3U7D2_MOUSE | Ribosomal protein L15 | up | 1.52 | 1.049 | 1.285 |
| 24   | tr|Q3TGQ3|Q3TGQ3_MOUSE | Putative uncharacterized protein | up | 1.401 | 1.53 | 1.466 |
| 25   | tr|Q3TLJ9|Q3TLJ9_MOUSE | Putative uncharacterized protein | up | 1.553 | 1.357 | 1.455 |
| 26   | sp|P62077|TIM8B_MOUSE | Mitochondrial import inner membrane translocase subunit Tim8 | up | 1.51 | 1.359 | 1.435 |
| 27   | tr|G5E850|G5E850_MOUSE | Cytochrome b-5, isoform CRA_a | up | 1.323 | 1.538 | 1.431 |
| 28   | sp|Q8B5Q7|K2C75_MOUSE | Keratin, type II cytoskeletal 75 | up | 1.203 | 1.771 | 1.487 |
| 29   | tr|D3Z125|D3Z125_MOUSE | Tumor protein D52 | up | 1.596 | 1.385 | 1.491 |
| 30   | sp|P45377|ALD2_MOUSE | Aldose reductase-related protein 2 | up | 1.759 | 1.442 | 1.601 |
| 31   | tr|B2RUC1|B2RUC1_MOUSE | Tpd52l1 protein | up | 1.425 | 1.699 | 1.562 |
| 32   | sp|P19001|K1C19_MOUSE | Keratin, type I cytoskeletal 19 | up | 1.727 | 1.819 | 1.773 |
| 33   | tr|A2A547|A2A547_MOUSE | Ribosomal protein L19 | up | 1.166 | 1.502 | 1.334 |
| 1    | tr|Q9D089|Q9D089_MOUSE | Putative uncharacterized protein | down | 0.929 | 0.597 | 0.763 |
| 2    | tr|J3QN31|J3QN31_MOUSE | Adenylosuccinate synthetase isozyme 1 | down | 0.499 | 0.504 | 0.502 |
| 3    | tr|F8VQ13|F8VQ13_MOUSE | Laminin subunit gamma-1 | down | 0.57 | 0.644 | 0.607 |
| 4    | sp|Q3UHD3|MTUS2_MOUSE | Microtubule-associated tumor suppressor candidate 2 homolog | down | 0.852 | 0.646 | 0.749 |

(Continued)
| Hits | Accession          | Protein name                                                                 | Expression   | 114/116 | 119/118 | Mean  |
|------|--------------------|------------------------------------------------------------------------------|--------------|---------|---------|-------|
| 5    | sp|Q61599|GDIR2_ MOUSE               | Rho GDP-dissociation inhibitor 2 | down       | 0.731   | 0.588 | 0.66  |
| 6    | tr|Q3TDU5|Q3TDU5_ MOUSE              | Milk fat globule-EGF factor 8 protein, isoform CRA_a | down       | 0.688   | 0.645 | 0.667 |
| 7    | sp|P16125|LDHB_ MOUSE                | L-lactate dehydrogenase B chain | down       | 0.179   | 0.165 | 0.172 |
| 8    | sp|Q8R3P0|ACY2_ MOUSE                | Aspartoacylase               | down       | 0.549   | 0.619 | 0.584 |
| 9    | sp|Q6ZPE2|MTMR5_ MOUSE               | Myotubularin-related protein 5 | down       | 0.634   | 0.875 | 0.755 |
| 10   | sp|Q8BFU3|RN214_ MOUSE               | RING finger protein 214      | down       | 0.652   | 0.866 | 0.759 |
| 11   | sp|Q61553|FSCN1_ MOUSE               | Fascin                       | down       | 0.273   | 0.282 | 0.278 |
| 12   | sp|P21981|TGM2_ MOUSE                | Protein-glutamine gamma-glutamyltransferase 2 | down       | 0.711   | 0.605 | 0.658 |
| 13   | sp|P17563|SBP1_ MOUSE                | Selenium-binding protein 1   | down       | 0.488   | 0.528 | 0.508 |
| 14   | sp|Q810Q5|NMES1_ MOUSE               | Normal mucosa of esophagus-specific gene 1 protein | down       | 0.807   | 0.515 | 0.661 |
| 15   | tr|E9PVM7|E9PVM7_ MOUSE              | Glutathione S-transferase Mu 5 | down       | 0.803   | 0.644 | 0.724 |
| 16   | sp|Q8BAV5|CB043_ MOUSE               | UPF0554 protein C2orf43 homolog | down       | 0.536   | 0.358 | 0.447 |
| 17   | tr|A2AE89|A2AE89_ MOUSE              | Glutathione S-transferase Mu 1 | down       | 0.473   | 0.652 | 0.563 |
| 18   | sp|P48428|TBCA_ MOUSE                | Tubulin-specific chaperone A  | down       | 0.661   | 0.76  | 0.711 |
| 19   | sp|Q4VAA2|CDV3_ MOUSE                | Protein CDV3                 | down       | 0.556   | 0.91  | 0.733 |
| 20   | sp|P08680|MAOX_ MOUSE              | NADP-dependent malic enzyme   | down       | 0.712   | 0.661 | 0.687 |
| 21   | sp|P60824|CIRBP_ MOUSE               | Cold-inducible RNA-binding protein | down       | 0.671   | 0.62  | 0.646 |
| 22   | tr|Q3UGY5|Q3UGY5_ MOUSE              | Putative uncharacterized protein | down       | 0.441   | 0.523 | 0.482 |
| 23   | sp|Q8BMK4|CKAP4_ MOUSE               | Cytoskeleton-associated protein 4 | down       | 0.336   | 0.529 | 0.433 |

(Continued)
| Hits | Accession   | Protein name                                      | Expression | 114/116 | 119/118 | Mean  |
|------|-------------|--------------------------------------------------|------------|---------|---------|-------|
| 24   | sp|P05063|ALDOC_MOUSE | Fructose-bisphosphate aldolase C | down       | 0.651  | 0.558  | 0.605 |
| 25   | tr|E0CY47|E0CY47_MOUSE | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1 | down       | 0.649  | 0.628  | 0.639 |
| 26   | tr|Q3TNC8|Q3TNC8_MOUSE | Putative uncharacterized protein | down       | 0.632  | 0.522  | 0.577 |
| 27   | sp|Q60928|GGT1_MOUSE | Gamma-glutamyltranspeptidase 1 | down       | 0.589  | 0.592  | 0.591 |
| 28   | sp|P14873|MAP1B_MOUSE | Microtubule-associated protein | down       | 0.62   | 0.618  | 0.619 |
| 29   | tr|Q5F2B1|Q5F2B1_MOUSE | Mannose-P-dolichol utilization defect 1 protein | down       | 0.797  | 0.661  | 0.729 |
| 30   | tr|Q3TJK3|Q3TJK3_MOUSE | Putative uncharacterized protein | down       | 0.551  | 0.468  | 0.51  |
| 31   | tr|Q3TDX7|Q3TDX7_MOUSE | Extracellular matrix protein 1 | down       | 0.451  | 0.388  | 0.42  |
| 32   | tr|Q8CEU1|Q8CEU1_MOUSE | Putative uncharacterized protein | down       | 0.644  | 0.74   | 0.692 |
| 33   | sp|P02798|MT2_MOUSE | Metallothionein-2 | down       | 0.727  | 0.65   | 0.689 |
| 34   | tr|I1E4X1|I1E4X1_MOUSE | Syntaxin-5 | down       | 0.642  | 0.59   | 0.616 |
| 35   | tr|Q3UNF3|Q3UNF3_MOUSE | Acyl-coenzyme A oxidase | down       | 0.726  | 0.646  | 0.686 |
| 36   | tr|Q4VAF0|Q4VAF0_MOUSE | Acylphosphatase | down       | 0.87   | 0.613  | 0.742 |
| 37   | tr|Q3TXK6|Q3TXK6_MOUSE | Putative uncharacterized protein | down       | 0.716  | 0.606  | 0.661 |
| 38   | tr|G3X8Q5|G3X8Q5_MOUSE | Ceruloplasmin | down       | 0.741  | 0.555  | 0.648 |
| 39   | tr|K4DI77|K4DI77_MOUSE | WD repeat-containing protein 81 | down       | 0.663  | 0.885  | 0.774 |
| 40   | tr|Q3TVJ0|Q3TVJ0_MOUSE | Putative uncharacterized protein | down       | 0.563  | 0.359  | 0.461 |

(Continued)
| Hits | Accession | Protein name | Expression | 114/116 | 119/118 | Mean |
|------|-----------|--------------|------------|---------|---------|-------|
| 41   | tr|Q1KYM0|Q1KYM0_ MOUSE | Env polyprotein | down | 0.661 | 0.614 | 0.638 |
| 42   | tr|Q3THB4|Q3THB4_ MOUSE | L-lactate dehydrogenase | down | 0.565 | 0.348 | 0.457 |
| 43   | tr|Q3U3U6|Q3U3U6_ MOUSE | Putative uncharacterized protein | down | 0.631 | 0.97 | 0.801 |
| 44   | sp|Q91ZX7|LRP1_ MOUSE | Pro-low-density lipoprotein receptor-related protein 1 | down | 0.577 | 0.708 | 0.643 |
| 45   | tr|Q3U2K1|Q3U2K1_ MOUSE | Putative uncharacterized protein | down | 0.629 | 0.915 | 0.772 |
| 46   | sp|Q8R180|ERO1A_ MOUSE | ERO1-like protein alpha | down | 0.674 | 0.602 | 0.638 |

33 proteins were upregulated and 46 were downregulated. Fold changes in abundance were also observed in two additional independent biological replicates.

Table 2: Top 25 KEGG pathways involving common exosome proteins

| No. | Pathway                                           | Proteins with pathway annotation | Pathway ID |
|-----|---------------------------------------------------|----------------------------------|------------|
| 1   | Metabolic pathways                               | 578 (15.72%)                     | ko01100    |
| 2   | RNA transport                                     | 145 (3.94%)                      | ko03013    |
| 3   | Spliceosome                                       | 141 (3.84%)                      | ko03040    |
| 4   | Pathways in cancer                               | 127 (3.45%)                      | ko05200    |
| 5   | Huntington's disease                             | 126 (3.43%)                      | ko05016    |
| 6   | Endocytosis                                       | 124 (3.37%)                      | ko04144    |
| 7   | Protein processing in endoplasmic reticulum      | 122 (3.32%)                      | ko04141    |
| 8   | Epstein-Barr virus infection                      | 122 (3.32%)                      | ko05169    |
| 9   | Regulation of actin cytoskeleton                 | 117 (3.18%)                      | ko04810    |
| 10  | Alzheimer's disease                              | 113 (3.07%)                      | ko05010    |
| 11  | Focal adhesion                                   | 106 (2.88%)                      | ko04510    |
| 12  | MAPK signaling pathway                           | 96 (2.61%)                       | ko04010    |
| 13  | Tight junction                                   | 96 (2.61%)                       | ko04530    |
| 14  | Parkinson's disease                              | 95 (2.58%)                       | ko05012    |

(Continued)
| No. | Pathway                                         | Proteins with pathway annotation | Pathway ID |
|-----|------------------------------------------------|----------------------------------|------------|
| 15  | HTLV-I infection                               | 94 (2.56%)                       | ko05166    |
| 16  | Influenza A                                    | 90 (2.45%)                       | ko05164    |
| 17  | Purine metabolism                              | 89 (2.42%)                       | ko00230    |
| 18  | Oxidative phosphorylation                      | 88 (2.39%)                       | ko00190    |
| 19  | Ribosome                                       | 86 (2.34%)                       | ko03010    |
| 20  | Insulin signaling pathway                      | 82 (2.23%)                       | ko04910    |
| 21  | Ubiquitin mediated proteolysis                 | 80 (2.18%)                       | ko04120    |
| 22  | mRNA surveillance pathway                      | 79 (2.15%)                       | ko03015    |
| 23  | Lysosome                                       | 75 (2.04%)                       | ko04142    |
| 24  | Herpes simplex infection                       | 72 (1.96%)                       | ko05168    |
| 25  | Ribosome biogenesis in eukaryotes              | 70 (1.9%)                        | ko03008    |

Figure 7: Bioinformatics analysis of proteins differentially expressed between Panc02 EXOs and Panc02-H7 EXOs. GO annotation of the final selected differentially expressed proteins, and KEGG pathway analysis. Differentially expressed proteins were classified by cellular component (CC), (A), molecular function (MF) (B), biological process (BP) (C), and pathway analysis (D) The top 10 CC, MF, BP, and pathway analysis components of the selected differentially expressed proteins are shown. Enrichment scores are represented as -log(p-values).
Table 3: Selected proteins identified in Panc02 EXOs and Panc02-H7 EXOs via iTRAQ quantitative proteomic analysis

| Category                      | Accession                      | Protein name          | ExoCarta |
|-------------------------------|--------------------------------|-----------------------|----------|
| ESCRT-1                       | tr|Q3UK08|Q3UK08_MOUSE          | TSG 101  | Yes      |
| ESCRT-associated              | sp|Q8R1T1|CHMP7_MOUSE           | CHMP7    | Yes      |
|                               | sp|Q9CQ10|CHMP3_MOUSE           | CHMP3    | Yes      |
|                               | tr|Q3TDX2|Q3TDX2_MOUSE          | VPS4A    | Yes      |
|                               | sp|Q9WU78|PDC6I_MOUSE           | PCD6IP/Alix | Yes     |
| Tetraspanins                  | sp|Q9CQ88|TSN31_MOUSE           | Tetraspanin-31 | No      |
|                               | tr|Q3UC80|Q3UC80_MOUSE          | CD63 antigen | Yes    |
|                               | tr|Q921J7|Q921J7_MOUSE          | Tetraspanin/CD151 | Yes   |
| Tetraspanins-associated       | tr|G3UYZ1|G3UYZ1_MOUSE          | IGSFM8   | Yes      |
| GTPase                        | tr|Q5SW88|Q5SW88_MOUSE          | RAB1A    | Yes      |
|                               | sp|Q9D1G1|RAB1B_MOUSE        | RAB1B    | Yes      |
|                               | sp|P53994|RAB2A_MOUSE        | RAB2A    | Yes      |
|                               | tr|Q6P7T7|Q6P7T7_MOUSE          | RAB2B    | Yes      |
|                               | tr|B2RRN5|B2RRN5_MOUSE          | RAB4A    | Yes      |
|                               | sp|Q9CQD1|RAB5A_MOUSE         | RAB5A    | Yes      |
|                               | tr|Q0P5D6|Q0P5D6_MOUSE          | RAB5B    | Yes      |
|                               | tr|Q8C266|Q8C266_MOUSE          | RAB5C    | Yes      |
|                               | tr|Q3U4W5|Q3U4W5_MOUSE          | RAB6     | Yes      |
|                               | sp|P51150|RAB7A_MOUSE         | RAB7A    | Yes      |
|                               | tr|Q3UH5W|Q3UH5W_MOUSE          | RAB8A    | Yes      |
|                               | sp|P61028|RAB8B_MOUSE         | RAB8B    | Yes      |
|                               | tr|A2AFP4|A2AFP4_MOUSE         | RAB9A    | Yes      |
|                               | sp|P61027|RAB10_MOUSE         | RAB10    | Yes      |
|                               | sp|P46638|RB11B_MOUSE         | RAB11B   | Yes      |
|                               | tr|A2CG35|A2CG35_MOUSE         | RAB12    | Yes      |
|                               | tr|Q50HXO|Q50HX0_MOUSE          | RAB14    | Yes      |
|                               | sp|P35293|RAB18_MOUSE         | RAB18    | Yes      |
|                               | tr|Q6A0C7|Q6A0C7_MOUSE         | RAB21    | Yes      |
|                               | tr|A2ARZ7|A2ARZ7_MOUSE         | RAB22A   | Yes      |
|                               | tr|Q3TXV4|Q3TXV4_MOUSE         | RAB22B   | Yes      |
|                               | tr|Q9D419|Q9D419_MOUSE         | RAB23    | Yes      |
|                               | tr|Q0PD20|Q0PD20_MOUSE         | RAB34    | Yes      |
|                               | sp|Q6PHN9|RAB35_MOUSE         | RAB35    | Yes      |

(Continued)
| Category                  | Accession               | Protein name                  | ExoCarta |
|---------------------------|-------------------------|-------------------------------|----------|
| Syntenin                  | sp|Q99JZ0|SDCB2_MOUSE                   | Syntenin-2 | Yes |
| SNARE                     | tr|B0QZN5|B0QZN5_MOUSE                   | VSMP 2    | Yes |
|                           | sp|P63024|VAMP3_MOUSE                    | VSMP 3    | Yes |
|                           | tr|Q8BSN6|Q8BSN6_MOUSE                   | VSMP 4    | No  |
|                           | sp|P70280|VAMP7_MOUSE                    | VSMP 7    | Yes |
|                           | sp|O70404|VAMP8_MOUSE                    | VSMP 8    | Yes |
| Internalization motif     | tr|A2APM1|A2APM1_MOUSE                   | CD44 antigen | Yes |
|                           | sp|Q62351|TFR1_MOUSE                     | Transferrin receptor protein 1 | Yes |
| Protein binding domain    | sp|Q9WV91|FPRP_MOUSE                     | Prostaglandin F2 receptor negative regulator | Yes |
| Heat shock protein        | sp|P17879|HS71B_MOUSE                    | Heat shock 70 kDa protein 1B | Yes |
|                           | tr|Q3UIF3|Q3UIF3_MOUSE                   | Heat shock protein HSP 90-alpha | Yes |
|                           | tr|Q3UBU0|Q3UBU0_MOUSE                   | Hsp90b1   | Yes |
|                           | sp|Q61699|HS105_MOUSE                    | Heat shock protein 105 kDa | Yes |
| Annexin                   | tr|Q3U5N9|Q3U5N9_MOUSE                   | Annexin A1 | Yes |
|                           | tr|Q9CZI7|Q9CZI7_MOUSE                   | Annexin A2 | Yes |
|                           | tr|Q3U737|Q3U737_MOUSE                   | Annexin A3 | Yes |
|                           | sp|P97429|ANXA4_MOUSE                    | Annexin A4 | Yes |
|                           | sp|P48036|ANXA5_MOUSE                    | Annexin A5 | Yes |
|                           | tr|Q3TU11|Q3TU11_MOUSE                   | Annexin A6 | Yes |
|                           | tr|Q3TJ49|Q3TJ49_MOUSE                   | Annexin A7 | Yes |
|                           | tr|Q921D0|Q921D0_MOUSE                   | Annexin A8 | Yes |
|                           | sp|P97384|ANX11_MOUSE                    | Annexin A11 | Yes |
| Adhesion                  | tr|Q3UGY5|Q3UGY5_MOUSE                   | Fibronecin | Yes |
|                           | sp|P09055|ITB1_MOUSE                     | Integrin beta-1 | Yes |
|                           | sp|Q62470|ITA3_MOUSE                     | Integrin alpha-3 | Yes |
|                           | sp|O54890|ITB3_MOUSE                     | Integrin beta-3 | Yes |
|                           | sp|A2A863|ITB4_MOUSE                     | Integrin beta-4 | Yes |
|                           | tr|Q80YP5|Q80YP5_MOUSE                   | Integrin alpha 5 | Yes |
|                           | tr|Q6PEE8|Q6PEE8_MOUSE                   | Integrin alpha-6 | Yes |
|                           | tr|A2AKI5|A2AKI5_MOUSE                   | Integrin alpha-V | Yes |
| S100                      | sp|P07091|S10A4_MOUSE                    | Protein S100-A4 | Yes |

(Continued)
| Category | Accession            | Protein name     | ExoCarta |
|----------|----------------------|------------------|----------|
|          | sp|P14069|S10A6_MOUSE | Protein S100-A6    | Yes     |
|          | tr|Q3UF30|Q3UF30_MOUSE | Protein S100-A10  | Yes     |
|          | sp|P50543|S10AB_MOUSE | Protein S100-A11  | Yes     |
|          | sp|P97352|S10AD_MOUSE | Protein S100-A13  | Yes     |
|          | sp|P50114|S100B_MOUSE | Protein S100-B    | Yes     |

Presence or absence of detected proteins in the ExoCarta database is noted.

Figure 8: Validation of iTRAQ quantitative proteomic analysis results. Western blotting validated differential expression patterns for six candidate proteins. FAR2, IGF2BP1, and S100A11 were upregulated, and SBP1, CKAP4, and ALDOC were down regulated in Panc02-H7 EXOs compared to Panc02 EXOs, in agreement with iTRAQ results. n=3/group. *P<0.05.

Figure 9: iTRAQ labeling experimental design schematic. Panc02 and Panc02-H7 cell-derived exosomes (EXO) were labeled with iTRAQ tags, 116 and 114, respectively, and another pair of biological replicates of the same samples was labeled with iTRAQ tags, 118 and 119, respectively.
Exosome treatment increased both CD11b+ and CD45+ hematopoietic progenitor cells in the liver, and activated Stat5 in myeloid cells. Wen, et al. showed that highly metastatic breast cancer-derived exosomes were taken up by CD45+ BMDCs [27]. Subsequent conditioning of naïve mice promoted MDSC accumulation and immune suppressive microenvironment formation in the lung and liver. Breast cancer exosomes also directly suppressed T-cell proliferation and inhibited NK cell cytotoxicity, likely suppressing the anti-cancer immune response in pre-metastatic organs [27]. Our results also showed that pancreatic cancer-derived exosomes increased MDSC (CD11b+GR1+ cells) frequency in peripheral blood after exosome “education.”

We found that Panc02-H7 cell-derived exosomes induced liver pre-metastatic niche formation in naïve mice and consequently increased primary tumor growth and liver metastatic burden. We then identified exosomal proteins from Panc02 and Panc02-H7 cells via iTRAQ-based quantitative proteomic analysis. iTRAQ is currently one of the most robust methods of peptide labeling-based protein quantification. Our study identified more proteins than previous exosome proteomic studies [28–29], and nearly all of the 25 proteins most frequently identified in the ExoCarta databank as exosomal markers (http://exocarta.org/exosome_markers).

The profuse desmoplastic stroma forces pancreatic cancer cells to adapt their metabolisms to the hostile microenvironment. Metabolic reprogramming is essential for cancer cell survival and optimized growth in metastatic site microenvironments [30–31], and was recently recognized as a pancreatic cancer hallmark [32]. Cancer cell metabolic reprogramming may be a key pancreatic cancer progression and metastasis driver. Pathway analysis of differentially expressed proteins revealed that exosomal proteins are related to metabolism and cancer-related signaling pathways, including pyruvate metabolism, glutathione metabolism, glycolysis/gluconeogenesis, and alanine, aspartate, and glutamate metabolism.

In conclusion, our analyses demonstrated that metabolism-related signaling pathways were involved in exosome-mediated intracellular communication. We found that Panc02-H7-derived exosomes reduced Panc02 cell adhesion, and increased migration and invasion, enhancing the metastatic nature of these cells. In a mouse model, Panc02-H7 exosomes induced liver pre-metastatic niche formation and promoted primary tumor growth and liver metastasis. Further studies are needed to confirm whether the exosome-specific proteins identified in our bioinformatics studies are potential candidate pancreatic cancer diagnostic/prognostic markers or novel therapeutic targets.

**MATERIALS AND METHODS**

**Chemicals and reagents**

RPMI 1640, fetal bovine serum (FBS), proteases, proteases inhibitors, and antibiotics were purchased from Gibco-BRL (Shanghai, China). PKH67 membrane dye and 5-(N, N-Dimethyl) amidolride hydrochloride (DMA) were purchased from Sigma-Aldrich (MO, USA). Trans-well chambers were purchased from Corning Life Sciences (MA, USA). All iTRAQ reagents and buffers were purchased from Applied Biosystems, Inc. (Foster City, CA). All other reagents were of the highest analytical grades available and unless otherwise stated were purchased from Sigma-Aldrich (MO, USA).

**Cell lines and cultures**

Corbett, et al. originally established the Panc02 murine PDAC cell line [33]. Wang, et al. established the Panc02-H7 sub-line using an in vivo selection method [11]. Panc02-H7 cells are highly aggressive after implantation, with progressive growth in the pancreas, peritoneal dissemination, and distant metastasis to multiple organs, including the liver and lungs. All cell lines were gifted from Dr. Min Li (M.D. Anderson Cancer Center, USA). Cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 units/ml penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B, and incubated at 37°C in humidified air with 5% CO2.

**Mice**

Female C57BL/6 mice were purchased from Nanjing Chinchilla Technology Co. Ltd. (Nanjing, China) and used at 4–6 weeks of age. Animal experiments abided by the Guidelines for Animal Care and Use issued by the Southeast University Medical School Institutional Animal Care and Use Committee.

**Exosome isolation and purification**

Panc02 and Panc02-H7 cells were cultured to 70% confluence in 75 cm2 flasks in RPMI-1640 medium supplemented with 10% exosome-free FBS, which had been depleted of bovine-derived exosomes by ultracentrifugation for 70 min at 100,000 g, followed by filtration through a 0.2-μm filter from Millipore (MA, USA). Supernatants collected from flasks were pelleted by centrifugation at 500 g for 10 min and 2,000 g for 20 min, resulting in floating cells and cell debris, respectively, and then further centrifuged at 20,000 g for 30 min to pellet larger microvesicles (MVs). Crude exosomes were prepared via ultracentrifugation of the supernatant at 100,000 g for 70 min, washing in PBS, and pelleting again by ultracentrifugation at 100,000 g for 70 min. Ultracentrifugation was always performed at 4°C. Crude exosome pellets were resuspended in 1 ml PBS and then filtered (0.22 μm). Purified exosomes were obtained as previously described with minor modification [28]. Briefly, PBS-suspended exosome preparations were diluted in 3.5 ml PBS and layered on top of a density cushion composed of 20 mM Tris/30% sucrose/
deuteriumoxide (D_2O)/HCl pH 7.35 (0.5 ml) forming a visible interphase. Samples were ultracentrifuged at 100,000 g for 70 min. Exosomes contained in the 30% sucrose/D_2O/Tris cushion and interphase were diluted five times with PBS and centrifuged at 120,000 g for 70 min. The final exosome pellets (Panc02 EXO and Panc02-H7 EXO) of higher purity were resuspended in PBS. We measured purified exosome total protein concentrations using the Bradford assay (Bio-Rad Laboratories, Hercules, CA), and purified exosome were stored at -80°C until use.

**Transmission electron microscopy (TEM)**

Purified exosomes were fixed in 2% paraformaldehyde (w/v) in 200 mM phosphate buffer (pH 7.4). Fixed exosomes were dripped onto Formvar carbon-coated 200 mesh copper grids and absorbed at roomtemperature (RT) for 10 min. Excess liquid was removed with filter paper. Adsorbed exosomes were negatively stained with 3% phosphotungstic acid at RT for 5 min, dried with an incandescent lamp for 2 min, and observed via TEM (JEM-2010; JEOL, Ltd., Tokyo, Japan) operating at 80.0 kV. Images were obtained using a cooled slow CCD camera.

**Western blotting**

Exosome, cell, and liver tissue protein concentrations were measured with the Bradford assay. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidine difluoride (PVDF) membranes. Membranes were incubated with primary antibodies at 4°C overnight in a buffer containing 5% skim milk, and then with a horseradish peroxidase (HRP)-conjugated secondary antibody at 37°C for 2 h. For exosome validation, primary antibodies against TSG101 (1:1000), CD9 (1:1000), MHC-1 (1:1000), and Cytochrome C (1:1000) were purchased from Abcam (Cambridge, UK). For cell migration and invasion assays, primary antibodies against CXCR4 (1:500) and MMP-9 (1:500) were purchased from Boster (Wuhan, China). For liver pre-metastatic niche formation assays, primary antibodies against CD11b (1:1000), S100A8 (1:1000), and S100A9 (1:1000) were purchased from Abcam (Cambridge, UK). For MS-identified candidates, primary antibodies against FRA2 (1:1000), IGF2BP2 (1:1000), and S100A11 (1:1000) were purchased from Abcam (Cambridge, UK). Selenium binding protein 1 (SBP1, 1:500), CKAP4 (1:500), and aldolase C (ALDOC, 1:500) were purchased from Bioss(Beijing, China). Protein-band densities were analyzed quantitatively using ImageJ software (NIH, USA).

**Exosome fluorescent labeling and uptake assay**

Exosomes were stained following the manufacturer’s instructions. Briefly, Panc02-H7 EXOs were labeled using the green lipophilic fluorescent dye, PKH67 (Sigma-Aldrich, St. Louis, MO) for 5 min. The reaction was terminated via addition of exosome-free FBS. To remove excess dye, PKH67-labeled exosomes were pelleted at 100,000 g for 70 min, washed three times with PBS, and resuspended in RPMI-1640 medium. Panc02 cells were inoculated in 6-well plates with exosome-free medium for 24 h. Cells were incubated with labeled exosomes for 5 h, washed three times with PBS, fixed with 4% paraformaldehyde for 15 min, and mounted with DAPI nuclear stain (1:100, Life Technologies, Grand Island, NY). Images were obtained using an inverted fluorescence microscope (Carl Zeiss, Germany).

**MTT cell adhesion, wound-healing, and invasion assays**

For the cell adhesion assay, 96-well plates from Thermo Scientific (Shanghai China) were incubated at 37°C with Matrigel for 1 h and then terminated with PBS containing 1% BSA overnight. After exposure to PBS (control group), 100 μg/ml Panc02-H7 EXOs (EXO group), or 7 mmol/L amiloride (exosomes-depression, Exo-D group), for 24 h, Panc02 cells were suspended in serum-free medium. A Panc02 cell suspension (1×10^5 cells/100μl) was then added to each well and incubated at 37°C for 3 h. Plates were washed three times with PBS to remove unattached cells. Remaining Panc02 cells were reacted with MTT (5 mg/ml) for 4 h at 37°C, then dissolved in DMSO. The absorbance of each well was measured with ELX800 Absorbance Microplate Reader (Bio-TEK Co,Winooski, VT,USA) at 490 nm. OD values represent the number of adherent cells.

For the wound-healing assay, approximately 1×10^6 Panc02 cells were inoculated in 6-well plates. After cultures reached 60% confluence, the monolayer was scratched using a 100 μl pipette tip. Attached cells were washed twice with PBS and incubated with medium as described for the cell adhesion assay. Each group (control, EXO, and Exo-D) was cultured in triplicate. Wound healing was analyzed under a microscope and images were captured at 0 and 24 h. The denuded area was measured viaImageJ (http://rsbweb.nih.gov). Cell motility was quantified using the formula: % of recovery = (A_24-A_0)/A_0×100% (A_0 is the denuded area measured immediately after wounding, A_24 is the denuded area measured 24 h after incubation). After the experiment, cells were harvested and protein was extracted for Western-blot analysis.

For the Boyden chamber (invasion) assay, Panc02 cells were divided into three groups and pretreated for 24h as described adhesion assay. Cells (5×10^5) were harvested and inoculated into upper transwell chambers in 5% FBS RPMI-1640 medium. 20% FBS RPMI-1640 medium was added into the lower chamber. Following 24h incubation, chamber upper surfaces were wiped with
cotton swabs, and invading cells were fixed and stained with crystalviolet. Invading cells were counted in three randomly selected microscope fields for each transwell.

**Tissue distributions of pancreatic cancer-derived exosomes**

Purified exosomes were labeled using PKH67 as previously described. PKH67-labeled exosomes from Panc02 and Panc02-H7 cells were injected intravenously into syngeneic C57BL/6 mice (20 μg exosomes/mouse). At 24 hpi, liver, lung, spleen, kidney, brain, and bone marrow tissues were harvested. Bone marrow cells were flushed from both the tibia and femur for confocal microscopy. As controls, mice were injected with equivalent particle numbers of PKH67-labeled synthetic 100μm unilamellar liposomes. Fluorescence intensity was quantified using IPP6.0 software (Media Cybernetics) to assess PKH67-labeled exosome tissue distributions.

**Exosome-induced liver pre-metastatic niche formation assessment**

Panc02-H7- and Panc02-derived exosomes (10μg each) were injected intravenously (tail vein) into C57B/L6 mice every other day. PBS was used as a control. At 12 d post-injection (dpi), livers were harvested for IF and Western blotting analysis. Peripheral blood obtained from mice was assessed using flow cytometry.

**Exosome-induced pancreatic cancer growth and liver metastasis assessment**

We established a pancreatic-cancer SOI metastatic model with Panc02 cells in C57BL/6 mice as described in our previous study [33]. Panc02-H7 EXOs and Panc02 EXOs (10 μg) were injected intravenously (tail vein) into C57BL/6 mice three days per week, starting one week following SOI and continuing for three weeks. Mice were sacrificed 15 and 30 d after SOI. After anesthesia (isoflurane), mice were examined via laparotomy and thoracotomy. All solid organs were harvested and stained with hematoxylin and eosin (H&E) to assess metastases. Primary tumor volume was calculated using the formula: V = 0.5×a×b², where a and b represent the long and short diameters of the tumor, respectively. PBS was used as a control.

**H&E staining, IHC, IF, and Masson's trichrome staining**

Tumors and tissues were fixed in 10% neutral buffered formalin at least one day before paraffin embedding. Serial 4 μm sections were cut and stained with H&E for histopathological examination. Two pathologists independently counted the number of neutrophils in 10 high power fields. IHC analysis was performed on formalin-fixed, paraffin-embedded tissue sections. De-paraffinization, antigen retrieval, and antigen-antibody reactions were performed using an automated DAKO Envision with Dual Link system-HRP. Tissue sections were incubated with primary antibodies followed by HRP-conjugated secondary antibody (from DAKO envision kit). Primary antibodies against fibronectin (1:100), α-SMA (1:50), S100A8 (1:50), S100A9 (1:50), and F4/80 (1:50) were purchased from Proteintech (Wuhan, China). Stain was developed using diaminobenzidine and counterstained with haematoxylin. IHC analyses were evaluated by two pathologists.

For IF, murine liver tissues were embedded in optimal cutting temperature (OCT) medium and stored at -80°C. Tissue sections were fixed in ice-cold acetone, permeabilized in PBS with 0.1% Triton X-100, blocked in PBS with 8% normal goat serum, and stained with primary antibodies against α-SMA (1:50) (Santa Cruz). Tissue sections were then washed in PBS, stained with secondary antibodies conjugated to AlexaFluor 488 or AlexaFluor 594 (1:500, Life Technologies) and counter stained with DAPI (1:100, Life Technologies) to detect nuclei. Images were obtained with fluorescence microscopy (Olympus, BX43).

Masson's trichrome staining for connective tissue was performed according to the manufacturer's instructions (Abcam). IHC, IF, and Masson's trichrome staining images were processed and analyzed via IPP6.0 software (Media Cybernetics).

**Flow cytometry and antibodies**

Peripheral blood was obtained by retro-orbital bleeding directly into EDTA anticoagulant tubes (Sarstedt, Newton, NC). Red blood cells were lysed using ACK lysis buffer (Gibco-BRL, Shanghai, China). Fc-receptors were blocked using anti-CD16/CD32 (BD Bioscience, Bedford, MA) before cell suspensions were incubated with fluorochrome-conjugated antibodies (mouse-CD11b-FITC and mouse-Ly-6G (Gr-1) PE, eBioscience, CA, USA) diluted in PBS with 1% BSA. Flow cytometry was performed using a Cytomics FC 500 flow cytometer (Beckman Coulter). Data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).

**Protein preparation for quantitative proteomic analysis of pancreatic cancer-derived exosomes**

Exosomes were suspended in lysis buffer (7 M urea, 2 M thiourea, 4%CHAPS, 40 mM Tris-HCl, pH 8.5,1mM PMSF, 2mM EDTA), and sonicated in ice. Proteins were reduced with 10 mM DTT (final
concentration) at 56°C for 1 h and then alkylated with 55 mM IAM (final concentration) in the dark for 1 h. The reduced and alkylated protein mixtures were precipitated by adding 4×volume of chilled acetone at -20°C overnight. After centrifugation at 4°C and 30,000 g, the pellet was dissolved in 0.5 M TEAB (Applied Biosystems, Milan, Italy) and sonicated in ice. After centrifugation at 30,000 g and 4°C, the supernatant protein concentration was measured with the Bradford assay. Proteins in the supernatant were stored at -80°C until use.

**iTRAQ labeling and strong cation exchange fractionation**

Protein (100μg) from each exosome sample was digested with Trypsin Gold (Promega, Madison, WI, USA) at a 30:1 protein:trypsin ratio, at 37°C for 16 h, and then dried by vacuum centrifugation. Peptides were reconstituted in 0.5 M TEAB and processed according to the manufacturer’s protocol for 4-plex iTRAQ reagent. Briefly, one unit of iTRAQ reagent was thawed and reconstituted in 24 μl isopropanol. Samples were labeled with iTRAQ tags as follows: Panc02 EXO and Panc02-H7 EXO were labeled with iTRAQ tags, 116 and 114, respectively, and biological replicates of the same exosomes were labeled with iTRAQ tags, 118 and 119, respectively. Peptides were labeled with the isobaric tags, incubated at room temperature for 2 h, and then pooled and dried by vacuum centrifugation. Strong cation exchange (SCX) chromatography was performed with a LC-20AB HPLC pump system (Shimadzu, Kyoto, Japan). iTRAQ-labeled peptide mixtures were reconstituted with 4 ml buffer A (25 mM NaH$_4$PO$_4$ in 25% ACN, pH 2.7) and loaded onto a 4.6×250 mm Ultremex SCX column containing 5 μm particles. Peptides were eluted at a flow rate of 1 ml/min with a gradient of buffer A for 10 min, 5–60% buffer B (25mM NaH$_4$PO$_4$, 1 M KCl in 25% ACN, pH 2.7) for 27 min, and 60–100% buffer B for 1 min. The system was then maintained at 100% buffer B for 1 min before equilibrating with buffer A for 10 min prior to the next injection. Elution was monitored by measuring the absorbance at 214 nm, and fractions were collected every 1 min. Eluted peptides were pooled into 20 fractions, de-salted with a Strata X C18 column (Phenomenex), and vacuum-dried. The iTRAQ workflow is shown in Figure 9.

**LC-ESI-MS/MS analysis based on Q EXACTIVE**

Each fraction was resuspended in buffer A (2% ACN, 0.1%FA) and centrifuged at 20,000 g for 10 min. The average final peptide concentration was approximately 0.5 μg/μl. 10 μl supernatant was loaded on an LC-20AD nanoHPLC (Shimadzu, Kyoto, Japan) with the autosampler onto a 2-cm C18 trap column. Peptides were eluted onto a 10-cm analytical C18 column packed in-house. Samples were loaded at 8 μl/min for 4 min, and then the 44-min gradient was run at 300 nl/min from 2–35% B (98%ACN, 0.1%FA) followed by a 2-min linear gradient to 80% B, maintenance at 80% B for 4 min, and a return to 5% over 1 min. Peptides were subjected to nano-electrospray ionization followed by tandem mass spectrometry (MS/MS) in a QEXACTIVE (Thermo Fisher Scientific, San Jose, CA) coupled online to the HPLC. Intact peptides were detected in the Orbitrap at a resolution of 70,000. Peptides were selected for MS/MS using the high-energy collision dissociation (HCD) operating mode with a normalized collision energy setting of 27.0. Ion fragments were detected in the Orbitrap at a resolution of 17,500. A data-dependent procedure that alternated between one MS scan followed by 15 MS/MS scans was applied for the 15 most abundant precursor ions above a threshold ion count of 20,000 in the MS survey scan, with a following Dynamic Exclusion duration of 15 s. The electrospray voltage applied was 1.6 kV. Automatic gain control (AGC) was used to optimize the spectra generated by the Orbitrap. The AGC target for full MS was 3e6, and 1e5 for MS2. The m/z scan ranges were 350–2,000 Da for MS scans, and 100–1800Da for MS2 scans.

**MS data analysis**

Raw data files acquired from the Orbitrap were converted into MGF files using Proteome Discoverer 1.2 (PD 1.2, Thermo) (5600 ms converter) and the MGF files were searched. Protein identification was performed using the Mascot search engine (Matrix Science, London, UK; version 2.3.02) against uniprot+exosome (mouse) databases containing 78,156 sequences. For protein identification, a mass tolerance of 10 ppm was permitted for intact peptide masses and 0.05 Da for fragmented ions, with allowance for one missed cleavage in the trypsin digest. Gln->pyro-Glu (N-term Q), oxidation (M), and Deamidated (NQ) were the potential variable modifications, and Carbamidomethyl (C), iTRAQ 4 plex (K) were fixed modifications. Peptide charge states were set to +2 and +3. An automatic decoy database search was performed in Mascot by choosing the decoy checkbox, in which a random database sequence is generated and tested for raw spectra as well as the real database. To reduce the probability of false peptide identification, only peptides at the 95% confidence interval as determined by a Mascot probability analysis greater than “identity” were counted as identified. Each protein identification involved at least one unique peptide. Protein quantitation required that a given protein contain at least two unique spectra. Quantitative protein ratios were weighted and normalized by the median ratio in Mascot. We only used ratios with p<0.05, and only fold changes of >1.5 were considered significant.
**Bioinformatics analyses**

Protein functional annotations were conducted using Blast2GO against the non-redundant protein database (NR;NCBI). The KEGG database (http://www.genome.jp/kegg/) was used to classify and group these identified proteins. Gene Ontology (GO) is an international standardization of gene function classification system. It provides a dynamically-updated, controlled vocabulary to describe gene and gene product attributes in the organism. GO ontologies describe molecular function, cellular component, and biological process. KEGG PATHWAY is a collection of manually drawn pathway maps representing molecular interaction and reaction networks.

**Statistical analysis**

Quantitative data are presented as means±standard error of the mean (s.e.m.). Statistical analyses were performed using SPSS software, version 18.0. Data were compared using Student’s t-test. P<0.05 was considered significant. For functional enrichment analysis using DAVID, cluster with an enrichment score >1.3 (-log(p-value)) were considered significant (the geometric mean of the p-values in a significant cluster was <0.05).

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**GRANT SUPPORT**

We thank the the National Natural Science Foundation of China (program no. 81071967, 81502505 and 81572408) for financial support.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.2016; 66:7-30.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu Q, He J. Cancer statistics in China, 2015. CA Cancer J Clin.2016; 66:115-132.
3. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, Spalletta B, Eramo A, Hassan C, Tomao S. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP. 2006; 7:486-491.
4. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude mouse models. Adv. Drug Deliv. Rev. 2013; 65:383-390.
5. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21:139-146.
6. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBlu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature.2015; 523:177-182.
7. Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, Wei F, Lin YL, Moro A, Grogan T, Chiang S, Feinstein E, Schafer C, Farrell J, Wong DT. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem.2013; 288:26888-26897.
8. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, Garcia-Santos G, Williams C, Ararro Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015; 17:816-826.
9. Madhavan B, Yue S, Galli U, Rana S, Gross W, Muller M, Giese NA, Kalthoff H, Becker T, Buechler MW, Zoller M. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136:2616-2627.
10. Adamczyk KA, Klein-Scory S, Tehrani MM, Warnken U, Schmiegel W, Schnolzer M, Schwarte-Waldhoff I. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sci. 2011; 89:304-312.
11. Wang B, Shi Q, Abbruzzese JL, Xiong Q, Le X, Xie K. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol. 2001; 29:37-46.
12. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thoel A, Multhoff G, Haman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Reb C, Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010; 120:457-471.
13. Jeppeesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjaet L, Orntoft TF, Larsen MR, Ostenfeld MS. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics.2014; 14:699-712.
14. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013; 32:623-642.
15. Jung T, Castellana D, Klingbeil P, Cuesta Hernández I, Vitacolonna M, Orlicky DJ, Roßler SR, Brodt P, Zöller M. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009; 11:1093-1105.

16. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18:883-91.

17. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007; 256:137-165.

18. Xu Q, Wang Z, Chen X, Duan W, Li X, Sheng L, Ma J, Han L, Li W, Zhang L, Guo K, Ma Z, Wu Z, Wu E, Ma Q. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Oncotarget. 2015; 6:4717-4732.

19. Zhang W, Liu Y, Wang CW. S100A4 promotes squamous cell laryngeal cancer Hep-2 cell invasion via NF-kB/MMP-9 signal. Eur Rev Med Pharmacol Sci. 2014; 18:1361-1367.

20. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Batra SK, Jarnagin WR, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527:329-335.

21. Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Mallya K, Katsumata N, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kaur S, Jain M, McElwee J, Saint M, Bissell MJ. Characterization and proteomic analysis of ovarian cancer-derived exosomes. Oncotarget. 2016; 7:6816-6827.

22. Liang B, Peng P, Li H, Hu H, Li X, Shen X, Ji C, Wang L, Zhang M, Tao Y, Wang Y, Li S, Zhang Y. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics. 2013; 80:171-182.

23. Yi H, Zheng X, Song J, Shen R, Su Y, Lin D. Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis. Int J Clin Exp Pathol. 2015; 8:15719-15728.

24. Kimmelman AC. Metabolic Dependencies in RAS-Driven Cancers. Clin Cancer Res. 2015; 21:1828-1834.

25. Gottlieb E. p53 guards the metabolic pathway less travelled. Nat Cell Biol. 2011; 13:195-197.

26. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang H, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang Y, Chinn L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149:656-6570.

27. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Grisswold DP Jr, Schabel FM Jr. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984; 44:717-726.

28. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. Proc. Natl. Acad. Sci. 1992; 89:5645-5649.